Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Enliven Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BURLINGAME, CALIF., SEPT. 3, 2026 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES: WELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCEDATE: TUESDAY, SEPT.

ENLIVEN THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES

BURLINGAME, CALIF., AUG. 31, 2026 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THAT THE COMPANY WILL PRESENT DATA FROM THE ENABLE PHASE 1 CLINICAL TRIAL OF ELVN-001 IN AN ORAL AND A POSTER PRESENTATION AT THE SOCIETY OF HEMATOLOGIC ONCOLOGY (SOHO) ANNUAL MEETING, TAKING PLACE SEPTEMBER 9-12, 2026, AT THE GEORGE R.

ENLIVEN THERAPEUTICS ANNOUNCES ORAL AND POSTER PRESENTATIONS AT THE SOCIETY OF HEMATOLOGIC ONCOLOGY (SOHO) 2026 ANNUAL MEETING

ANNOUNCED POSITIVE PHASE 1 CLINICAL DATA FOR ELVN-001 IN CML, DEMONSTRATING ENCOURAGING ELVN-001 EFFICACY DATA AND A FAVORABLE SAFETY AND TOLERABILITY PROFILE REACHED ALIGNMENT WITH THE FDA ON KEY PHASE 3 TRIAL DESIGN COMPONENTS STRONG BALANCE SHEET WITH $895 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES, WHICH IS EXPECTED TO PROVIDE CASH RUNWAY INTO 2030 BURLINGAME, CALIF., AUG. 5, 2026 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AND PROVIDED A BUSINESS UPDATE.

ENLIVEN THERAPEUTICS REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

BURLINGAME, CALIF., JUNE 15, 2026 /PRNEWSWIRE/ --ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THAT IT HAS CLOSED ITS UPSIZED UNDERWRITTEN PUBLIC OFFERING OF 10,533,334 SHARES OF ITS COMMON STOCK, WHICH INCLUDES THE FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE 1,600,000 ADDITIONAL SHARES OF ITS COMMON STOCK, AT A PRICE TO THE PUBLIC OF $37.50 PER SHARE AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE 1,733,333 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $37.499 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE OF EACH SHARE OF ENLIVEN'S COMMON STOCK LESS THE $0.001 PER SHARE EXERCISE PRICE FOR EACH PRE-FUNDED WARRANT.

ENLIVEN THERAPEUTICS ANNOUNCES CLOSING OF UPSIZED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS AND FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

BURLINGAME, CALIF., JUNE 11, 2026 /PRNEWSWIRE/ --ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THAT IT HAS PRICED ITS PREVIOUSLY ANNOUNCED UPSIZED UNDERWRITTEN PUBLIC OFFERING OF 8,933,334 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $37.50 PER SHARE AND, IN LIEU OF COMMON STOCK TO INVESTORS WHO SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE UP TO 1,733,333 SHARES OF ENLIVEN'S COMMON STOCK AT A PRICE TO THE PUBLIC OF $37.499 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE OF EACH SHARE OF ENLIVEN'S COMMON STOCK LESS THE $0.001 PER SHARE EXERCISE PRICE FOR EACH PRE-FUNDED WARRANT.

ENLIVEN THERAPEUTICS ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

BURLINGAME, CALIF., JUNE 11, 2026 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $250.0 MILLION OF SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO INVESTORS WHO SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ENLIVEN'S COMMON STOCK.

ENLIVEN THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

61% OVERALL MMR AND 48% MMR ACHIEVEMENT BY 24 WEEKS IN THE 80 MG QD PHASE 1B COHORT 67% OVERALL MMR AND 55% MMR ACHIEVEMENT BY 24 WEEKS IN ALL PHASE 1B PATIENTS WHO HAD PREVIOUSLY RECEIVED 1 OR 2 PRIOR UNIQUE TKIS FAVORABLE SAFETY AND TOLERABILITY PROFILE WITH 161 PATIENTS ENROLLED AND A MEDIAN TREATMENT DURATION OF 35 WEEKS ALIGNMENT WITH THE FDA ON 80 MG QD AS THE RECOMMENDED PHASE 3 DOSE AND ON THE 2L+ PATIENT POPULATION FOR THE ENABLE-2 PIVOTAL TRIAL, WHICH IS EXPECTED TO INITIATE IN THE SECOND HALF OF THIS YEAR BURLINGAME, CALIF., JUNE 11, 2026 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY PRESENTED UPDATED POSITIVE DATA FROM THE PHASE 1 ENABLE CLINICAL TRIAL EVALUATING ELVN-001 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC MYELOID LEUKEMIA (CML).

ENLIVEN THERAPEUTICS ANNOUNCES UPDATED POSITIVE PHASE 1 CLINICAL DATA AND ALIGNMENT WITH FDA ON KEY PHASE 3 TRIAL DESIGN COMPONENTS

ENLIVEN WILL HOST AWEBCAST CONFERENCE CALLONJUNE11,AT8:30A.M.ET BURLINGAME, CALIF.

ENLIVEN THERAPEUTICS TO HOST WEBCAST CONFERENCE CALL TO DISCUSS PHASE 1 ELVN-001 CLINICAL DATA BEING PRESENTED AT EHA 2026 CONGRESS

BOULDER, COLO., MAY 21, 2026 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES: TD COWEN ANNUAL ONCOLOGY INNOVATION SUMMIT: INSIGHTS FOR ASCO & EHAFORMAT: FIRESIDE CHATDATE: WEDNESDAY, MAY 27TIME: 2:30 P.M.

ABSTRACT INCLUDES PREVIOUSLY REPORTED DATA: CUMULATIVE MMR RATE OF 47% WITH 38% OF PATIENTS ACHIEVING MMR BY 24 WEEKS IN MATURE, HEAVILY PRETREATED 80 MG QD PHASE 1B COHORT IN PATIENTS WHO PREVIOUSLY RECEIVED ASCIMINIB, CUMULATIVE MMR RATE WAS 52%, WITH 38% OF PATIENTS ACHIEVING MMR BY 24 WEEKS ELVN-001 MAINTAINED A FAVORABLE SAFETY AND TOLERABILITY PROFILE WITH 141 PATIENTS ENROLLED AND A MEDIAN TREATMENT DURATION OF ~32 WEEKS EHA PRESENTATION WILL INCLUDE UPDATED DATA WITH ADDITIONAL PATIENTS AND LONGER TREATMENT DURATION BOULDER, COLO., MAY 12, 2026 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED ADDITIONAL, POSITIVE DATA FROM THE PHASE 1 ENABLE CLINICAL TRIAL EVALUATING ELVN-001 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN AN ABSTRACT ACCEPTED FOR AN ORAL PRESENTATION AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2026 CONGRESS TAKING PLACE JUNE 11-14 IN STOCKHOLM, SWEDEN AND VIRTUALLY.

ENLIVEN THERAPEUTICS ANNOUNCES ORAL PRESENTATION AT THE EHA 2026 CONGRESS FEATURING ADDITIONAL POSITIVE PHASE 1 CLINICAL TRIAL DATA FOR ELVN-001 IN CML

Enliven Therapeutics, Inc.

ELVN

Price

Financial Reports

No items found.

Press Releases

Enliven Therapeutics, Inc.

ELVN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ELVN